Better Healthcare ETF: Invesco's Biotech-Focused IBBQ vs. iShares' Broad IYH

The Invesco Nasdaq Biotechnology ETF (IBBQ) offers lower costs (0.19% expense ratio) and higher 1-year returns (44.6%), making it suitable for growth-focused investors willing to accept volatility. The iShares U.S. Healthcare ETF (IYH) provides broader diversification across 100 healthcare holdings with higher dividend yield (1.1%) and lower volatility, appealing to conservative investors seeking stability and income.

09/22/2026, 10:04 PM • The Motley Fool

Aerska Appoints Laura Sepp-Lorenzino to Scientific Advisory Board

Aerska, a biotechnology company developing RNA medicines for CNS diseases through its antibody-oligonucleotide conjugate (AOC) platform, has appointed Laura Sepp-Lorenzino to its Scientific Advisory Board. Sepp-Lorenzino brings over 30 years of experience in genetic medicines and nucleic acid therapies, previously serving as Chief Scientific Officer at Intellia Therapeutics and leading nucleic acid programs at Vertex Pharmaceuticals.

09/17/2026, 8:00 AM • GlobeNewswire

My Top 5 Favorite Stocks for an Uncertain Market

The article recommends five resilient stocks suitable for uncertain market conditions: Johnson & Johnson (pharmaceutical and medtech leader with 28 billion-dollar products), Vertex Pharmaceuticals (cystic fibrosis treatment market leader with pipeline expansion), Costco (essential goods retailer with high membership renewal rates), Coca-Cola (beverage company with strong brands and free cash flow), and American Express (payment card company with affluent customer base). These companies offer stability through essential products, strong market positions, and consistent dividend payments.

09/16/2026, 7:10 AM • The Motley Fool

AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

The article compares AbbVie, a mature pharmaceutical company with stable cash flows and a growing immunology portfolio, against CRISPR Therapeutics, a clinical-stage biotech firm pioneering gene-editing therapies. AbbVie is recommended as the better choice for 2026 due to its profitability, strong free cash flow generation, and rising dividend, while CRISPR offers high-reward potential but faces significant cash burn and execution risks.

09/14/2026, 10:40 AM • The Motley Fool

Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

The article compares Amgen, an established pharmaceutical giant with $36.7B in revenue and a 2.60% dividend yield, against CRISPR Therapeutics, a gene-editing biotech pioneer with only $3.5M in revenue but groundbreaking CASGEVY therapy. While CRISPR offers high-growth potential, it remains unprofitable with significant losses. The author recommends Amgen for most investors seeking stability and predictable returns, though acknowledges CRISPR's improving commercial trajectory makes it a more compelling speculative opportunity than previously.

09/11/2026, 11:09 AM • The Motley Fool

Why CRISPR Therapeutics Stock Rocked the Market Last Month

CRISPR Therapeutics stock surged nearly 19% in August following strong Q2 earnings. The company's approved blood disorder treatment Casgevy saw 78% quarter-over-quarter sales growth to $76 million, and the FDA approved its label expansion for pediatric patients aged 2 and older. CRISPR also received a $10 million upfront payment from a licensing deal, significantly boosting revenue to $10.2 million and narrowing net losses compared to year-ago figures.

09/08/2026, 5:25 PM • The Motley Fool

Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?

The biotech industry is experiencing a strong rebound in 2026. While both Vertex Pharmaceuticals and Regeneron are attractive options, Vertex emerges as the better buy due to its stronger competitive advantage in cystic fibrosis drugs with patent protection until the late 2030s, diversified pipeline targeting high-need areas with less competition, and lower execution risk compared to Regeneron's dependence on weight-loss candidates and defending its Dupixent franchise against increasing competition.

09/04/2026, 2:30 PM • The Motley Fool

3 Stocks Whose Competitive Walls Tower Over Nvidia's

While Nvidia has built a strong competitive moat in AI chips, three healthcare stocks—Moderna, Intuitive Surgical, and Vertex Pharmaceuticals—possess even more formidable competitive advantages. Moderna leverages its mRNA expertise across vaccines and oncology; Intuitive Surgical dominates robotic surgery with high switching costs; and Vertex leads in cystic fibrosis treatment with a patent-protected pipeline extending to the late 2030s.

09/03/2026, 11:10 AM • The Motley Fool

Healthcare ETF Comparison: Fidelity's FHLC vs. Invesco's Biotech-Focused IBBQ

Fidelity's FHLC and Invesco's IBBQ offer different healthcare investment strategies. FHLC provides broad exposure to 365 healthcare holdings with a lower 0.08% expense ratio and 1.2% dividend yield, while IBBQ focuses on biotech with higher volatility, delivering 56.4% 1-year returns but experiencing a 37.9% maximum drawdown. The choice depends on investor risk tolerance and diversification preferences.

09/02/2026, 12:12 PM • The Motley Fool

Which Healthcare ETF Offers the Better Growth Outlook: VanEck Biotech or Invesco Pharmaceuticals?

The article compares two healthcare ETFs: VanEck Biotech ETF (BBH) with a lower 0.35% expense ratio and concentrated biotech focus, versus Invesco Pharmaceuticals ETF (PJP) with higher dividend yield and broader pharma exposure. Despite PJP's superior 5-year performance and lower volatility, the article concludes BBH is the better buy based on recent outperformance, though both funds offer targeted healthcare sector exposure with different risk-return profiles.

08/28/2026, 11:31 AM • The Motley Fool

Which Biotech ETF Is a Better Buy: Concentrated Bet or Broad Basket?

Invesco Nasdaq Biotechnology ETF (IBBQ) emerges as the better choice over VanEck Biotech ETF (BBH) for most investors. IBBQ offers broader diversification with 251 holdings, lower fees (0.19% vs 0.35%), higher dividend yield (0.8% vs 0.4%), and superior 5-year returns ($1,338 vs $1,061 on $1,000 invested). While BBH's concentrated 25-stock portfolio provides focused exposure to biotech leaders, it carries higher single-company risk without compensating benefits.

08/22/2026, 7:05 AM • The Motley Fool

IBBQ vs. PBE: Which Biotech ETF Is the Better Buy?

The article compares two biotech ETFs from Invesco: IBBQ, which offers broad diversification across 251 companies with a low 0.19% expense ratio, and PBE, which takes a concentrated approach with 31 holdings and a higher 1.73% dividend yield. IBBQ is recommended for long-term investors seeking low-cost exposure, while PBE appeals to income-focused investors willing to pay higher fees for selective, momentum-driven picks.

08/21/2026, 7:02 AM • The Motley Fool

Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead

Vertex Pharmaceuticals strengthens its dominant position in the cystic fibrosis market after competitor Sionna Therapeutics failed a clinical trial for its CF drug candidate. With continued CF portfolio improvements, patent exclusivity until the late 2030s, and promising newer medicines like Casgevy for rare blood diseases and Journavx for pain management, Wall Street remains bullish on Vertex's growth prospects.

08/20/2026, 3:30 PM • The Motley Fool

Invesco Nasdaq Biotech vs. Invesco Pharma: How Do These ETFs Stack Up?

The Invesco Pharmaceuticals ETF (PJP) offers concentrated exposure to 29 pharma giants with better historical returns and lower volatility, while the Invesco Nasdaq Biotechnology ETF (IBBQ) provides broader diversification across 251 holdings at a lower expense ratio of 0.19% versus 0.57%. Despite IBBQ's cost advantage, PJP is recommended as the better buy due to its significantly larger asset base ($512.6M vs $81M), which addresses liquidity concerns.

08/19/2026, 7:15 AM • The Motley Fool

State Street XLV vs VanEck BBH: Which Healthcare ETF Is the Better Buy in 2026?

State Street's XLV healthcare ETF offers broader exposure with lower costs (0.08% expense ratio) and higher dividend yield (1.6%), delivering 30% more growth over five years with lower volatility. VanEck's BBH biotech ETF provides concentrated exposure to 25 biotech stocks with higher recent returns but greater risk, making XLV the better choice for long-term investors seeking defensive characteristics.

08/05/2026, 3:02 PM • The Motley Fool